This was no doubt a bittersweet deal for Joseph Edelman’s Perceptive Advisors.
When Kodiak Sciences was gearing up to go public earlier this month, the developmental-stage biopharmaceutical company planned to offer 9 million shares for between $13 and $15 per share.
But when it finally began trading on October 4, the IPO was priced at just $10 per share.
